LipoNova signs MoU for Reniale

Hannover, Germany-based LipoNova AG says that it has signed a memorandum of understanding for the development and marketing of its product candidate Reniale, claimed to be the world's first autologous vaccine for non-metastatic renal cell carcinoma, with a respected non-European pharmaceutical company.

The MoU provides for milestone payments and ongoing sales-related royalties based on the turnover of Reniale. Further financial details were not disclosed. LipoNova's partner, which is unnamed, is being granted an exclusive licence for a non-European country for this purpose. After conclusion of the agreement, the partner will actively support the international Phase III study and be involved in possible "named patients" programs.

The German firm says it aims to launch Reniale, which has completed Phase III clinical evaluation on adjuvant RCC, on other non-European markets.